Press release
08.06.2015

Adents raises €8.5 millions in funding

Massy, France – Adents, a leading product unit identification and traceability software provider, has secured €8.5 million in additional funding. This round of financing will allow the fast-growing company to expand its international presence and ensure the rapid deployment of its software solution on pharmaceutical product packaging lines in Europe and North America.

Founded in 2007, Adents has quickly become a major player in product unit identification and traceability software in France, particularly in the pharmaceutical sector. In a context where counterfeit medicines are flooding the internet and arrive at the pharmacy or hospital, sometimes becoming part of the official distribution channel and putting millions of lives in danger, principal countries across the globe have passed anticounterfeiting legislation. In order to protect patients, the pharmaceutical industry must now identify each drug pack individually using a unique code. This further step in serialization must be implemented for the global production of prescription medicines worldwide by the end of 2018.

With over 25 years’ of experience in traceability, Adents’ founders have developed a new generation of software which allows laboratories and contract manufacturers to conform
to regulations on time and in accordance with national specificities. As the only standard serialization solution on the market, Adents’ software offers the major advantage of fast, easy deployment while limiting disruptions to production. Today, more than one billion codes have already been generated and piloted by Adents’ software.

The capital increase of €8.5 million is led by existing shareholders NAXICAP Partners and CapHorn Invest, its historical shareholders, Omnes Capital and members of the
management team. The funding will allow Adents to support its continued growth in Europe and North America, where the company has just opened two subsidiaries: Adents
Canada Inc. and Adents US Inc.

“These funds will allow us to establish a presence in major European countries. We are going to be in a position to meet the needs of the pharmaceutical industry picking up
speed with approaching regulation deadlines”, added Christophe Devins, Adents CEO and co-founder. “Adents has developed a mature and unique technology which enables the
pharmaceutical industry to comply with the new worldwide legislations. The software company is in a very good position to become a global leader on a market which represents several billion euros globally”, adds Michel de Lempdes, Managing Director, Omnes Capital.

CONTACT
Christopher DALE
+1 (973) 227-8080 ext. 116
cdale@turchette.com

LATEST PRESS RELEASES

At Interpack, Adents to Demonstrate Pharmaceutical Serialization Software that Secures Supply Chain and Fights Counterfeiting
Adents will showcase its latest serialization and traceability solutions to secure the pharmaceutical supply chain from May 4-10 at Interpack 2017 at Hall 6, Booth D10. Adents will showcase its two primary products: Adents Seriza and Adents Prodigi in collaboration with Siemens, Microsoft, Supply Chain Wizard and Germark.
18.04
2017
+
Tris Pharma Chooses Software from Adents to Meet Serialization Compliance Regulations
Tris Pharma – a specialty pharmaceutical company engaged in research, development, and manufacturing of both OTC and Rx branded and generic products – has chosen software from Adents, a leading provider of versatile and easily deployable serialization and track-and-trace software solutions, to assure compliance with upcoming U.S. serialization deadlines.
05.04
2017
+
At INTERPHEX NYC, Adents and Microsoft to Jointly Present Adents Prodigi Cloud Serialization and Traceability Solution
Adents in collaboration with Microsoft, will introduce to the U.S. market Adents Prodigi, a new Cloud serialization and traceability solution. Adents Prodigi enters the market as the only Level 4 traceability solution that can centrally manage regulatory requirements mandated in the pharmaceutical industry, as well as allow pharmaceutical companies and CMOs to take advantage of the massive amounts of data generated during the serialization and track & trace process.
02.03
2017
+